Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

@article{Giovannoni2011SustainedDS,
  title={Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis},
  author={Gavin Giovannoni and Stuart D. Cook and Kottil Rammohan and Peter Rieckmann and Per Soelberg S{\o}rensen and Patrick Vermersch and Anthony Hamlett and Vissia Viglietta and Steven J. Greenberg},
  journal={The Lancet Neurology},
  year={2011},
  volume={10},
  pages={329-337}
}

Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment

TLDR
Post hoc evidence suggests consistent treatment benefits of cladribine tablets 3.5 mg/kg in HDA patient subgroups that were either treated with disease-modifying drugs (DMDs) prior to study entry or were treatment naïve.

Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study

TLDR
Patients with HDA showed clinical and MRI responses to Cladribine Tablets 3.5 mg/kg that were generally better than, or at least comparable with, the outcomes seen in the overall CLARITY population.

Disease-activity-free status in patients with relapsing–remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study

TLDR
DAC HYP resulted in a meaningful increase in the proportion of relapsing–remitting MS patients who were disease-activity free versus placebo at one year, according to a post-hoc analysis of the SELECT trial.

No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis

TLDR
It is suggested that fingolimod therapy results in a higher probability of NEDA than dimethyl fumarate and teriflunomide therapy when phase 3 trial data are indirectly compared and differences between trials are adjusted for.

No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study

TLDR
The proportion of patients with relapsing-remitting MS achieving NEDA in the DECIDE study of daclizumab versus intramuscular interferon beta-1a patients was assessed, with effects increasing over time.

Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)—a systematic review protocol

TLDR
The primary objective of this review is to assess the differential treatment effects of all approved DMTs in subgroups of adults with clinically isolated syndrome or relapsing forms of MS and to analyse the evidence on TEM in MS immunotherapy to support clinical decision making in individual cases.

Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study

TLDR
Previous data about cladribine effectiveness on disease activity and disability worsening and information on response predictors that might inform therapeutic choices are confirmed and provided.
...

References

SHOWING 1-10 OF 34 REFERENCES

Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study

TLDR
The safety and tolerability profile observed in the CLARITY study together with the reported efficacy support the potential for cladribine tablets as an MS therapy.

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

TLDR
Both doses of oral fingolimod improved the relapse rate, the risk of disability progression, and end points on MRI and were superior to placebo with regard to MRI-related measures.

The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis-preliminary results

TLDR
It is suggested that short-term measurement of the number of gadolinium enhancing lesions may predict long term outcome in relapsing-remitting MS.

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

TLDR
Treatment with cladribine tablets significantly reduced relapse rates, the risk of disability progression, and MRI measures of disease activity at 96 weeks, and the benefits need to be weighed against the risks.

Measures in the first year of therapy predict the response to interferon β in MS

TLDR
In RRMS patients treated with IFNβ, the combination of measures of disease activity and the presence of new active lesions on MRI may have a prognostic value for identifying patients with disease activity in the second and third year of therapy.

Freedom from disease activity in multiple sclerosis

TLDR
This work discusses some potential definitions of disease remission in MS and whether freedom from disease activity can become an increasingly useful measure of therapeutic response and decides the long-term significance of freedom from Disease activity during a short-term clinical trial in relapsing-remitting MS.